Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-COVID19-B Booster vs Vaxzevria in Adults
NCT05534035Phase 3Unknown
- Sponsor
- Everest Medicines
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of PTX-COVID19-B in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Everest Medicines. Primary endpoint: Immunogenicity Response at Day 15. Status: unknown.
02
Drugs
PTX-COVID19-B
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05534035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534035.